PedAM
Pediatric Disease Annotations & Medicines
| Disease | lymphoma |
| Phenotype | C0085110|severe combined immunodeficiency |
| Sentences | 2 |
| PubMedID- 22150234 | In an in vivo severe combined immunodeficiency mouse model of human lymphoma, ofatumumab prolonged median survival compared to rituximab. |
| PubMedID- 25072059 | In a severe combined immunodeficiency (scid) mouse model of disseminated residual lymphoma, anti-cd20-rli was found to induce long-term survival of 90% of mice up to at least 120 days whereas rli and rtx, alone or in combination, just delayed the disease onset (100% of death at 28, 40 and 51 days respectively). |
Page: 1